Proposed Data Collection Submitted for Public Comment and Recommendations, 85215-85216 [2024-24922]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2024–24921 Filed 10–24–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–25–1385; Docket No. CDC–2024–
0084]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Characteristics
of Cases of Priority Fungal Diseases.
These case report forms (CRF) collect
information on patient demographics,
underlying conditions, diagnosis,
treatments, healthcare utilization, and
outcomes of patients with
coccidioidomycosis, histoplasmosis,
blastomycosis, Candida auris, triazoleresistant Aspergillus fumigatus infection
or colonization, or antifungal-resistant
dermatophytosis, chromoblastomycosis,
mycetoma, and sporotrichosis.
DATES: CDC must receive written
comments on or before December 24,
2024.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2024–
0084 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
ddrumheller on DSK120RN23PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
17:40 Oct 24, 2024
Jkt 265001
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385, Exp. 4/30/2027)—
Revision—National Center for Emerging
and Zoonotic Infectious Diseases
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
85215
(NCEZID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Fungal diseases cause substantial
illness, ranging from mild infection to
severe or life-threatening invasive
disease. They also constitute a
considerable financial burden on
patients and healthcare systems.
Awareness of fungal diseases is low,
and data collection has historically been
limited in size, scope, and coordination,
which has hindered our understanding
of these diseases. Detailed
epidemiologic and clinical data are
critical to inform appropriate public
health responses.
CDC plans to enhance surveillance of
high priority fungal diseases across the
United States to better characterize
factors such as disease burden,
geographic scope, patient risk factors,
health disparities, healthcare utilization,
outcomes, and emerging trends. This
project will serve as a Revision to the
information collection project
Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385). The Revision will expand
the number of fungal diseases for which
data may be collected. In addition to
triazole-resistant A. fumigatus
infections, coccidioidomycosis,
histoplasmosis, blastomycosis, C. auris,
and antifungal-resistant
dermatophytosis, Case Report Forms
(CRF) have also been developed for
chromoblastomycosis, mycetoma, and
sporotrichosis.
CDC plans to use standardized CRFs
to collect public health surveillance
data for cases of these diseases regarding
demographics (e.g., age, sex, race/
ethnicity, location of residence),
underlying medical conditions,
diagnosis (e.g., clinical presentation,
laboratory testing), treatments, and
outcomes (e.g., hospitalization, vital
status). The corresponding CRF would
be filled out voluntarily by state, local
or tribal health departments, federal
agencies, and members of the private
sector (e.g., academic institutions), and
contains a section for medical chart
review and an optional supplemental
interview (including data on potential
occupational or environmental
exposures) of the patient or their
representative. Findings can help
identify populations at higher risk of
these diseases, detect emerging
epidemiologic trends, and guide
prevention and response efforts. They
can also help better focus public and
healthcare provider outreach, inform
efforts to contain or mitigate spread, and
influence health policy and research on
prevention and treatment.
E:\FR\FM\25OCN1.SGM
25OCN1
85216
Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices
CDC requests OMB approval for an
estimated 1,564 annual burden hours.
There is no cost to respondents other
than their time to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Number
responses per
respondent
Avg. burden
per
response
(in hrs.)
Total
burden
(in hrs.)
Type of respondent
Triazole-resistant Aspergillus fumigatus Case Report Form
Coccidioidomycosis Case Report Form ................................
Antifungal-resistant dermatophytosis case report form ........
Chromoblastomycosis case report form ...............................
Mycetoma case report form ..................................................
Sporotrichosis case report form ............................................
State and Local Health Departments ....
State and Local Health Departments ....
Private Sectors ......................................
State and Local Health Departments ....
Private Sectors ......................................
State and Local Health Departments ....
Private Sectors ......................................
State and Local Health Departments ....
Private Sectors ......................................
State and Local Health Departments ....
Private Sectors ......................................
Private Sectors ......................................
Private Sectors ......................................
15
10
3
10
3
10
3
15
3
10
25
25
25
15
25
10
25
10
25
10
20
10
10
10
5
10
0.5
1.0
1.0
1.0
1.0
1.0
1.0
0.75
0.75
0.5
0.5
0.5
0.5
113
250
30
250
30
250
30
225
23
50
125
63
125
Total ...............................................................................
...............................................................
......................
..........................
....................
1,564
Histoplasmosis Case Report Form .......................................
Blastomycosis Case Report Form ........................................
Candida auris Case Report Form .........................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–24922 Filed 10–24–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Lead Exposure and
Prevention Advisory Committee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention announces the following
meeting for the Lead Exposure and
Prevention Advisory Committee
(LEPAC). This virtual meeting is open to
the public. Advance registration by
December 4, 2024, is needed to receive
the information to join the meeting. The
registration link is provided in the
addresses section below.
DATES: The meeting will be held on
December 11, 2024 from 11 a.m. to 5
p.m., EST.
ADDRESSES: Register in advance https://
events.gcc.teams.microsoft.com/event/
0e538aa3-bc82-43e9-89ee-d997b498c
fe6@9ce70869-60db-44fd-abe8-d27670
77fc8f to receive information to join the
meeting.
FOR FURTHER INFORMATION CONTACT: Paul
Allwood, Ph.D., M.P.H., Designated
Federal Officer, National Center for
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
respondents
Form name
VerDate Sep<11>2014
17:40 Oct 24, 2024
Jkt 265001
Environmental Health, Centers for
Disease Control and Prevention, 4770
Buford Highway, Atlanta, Georgia
30341, Telephone: 770–488–6774;
Email: LEPAC@cdc.gov.
SUPPLEMENTARY INFORMATION:
Background: The Lead Exposure and
Prevention Advisory Committee was
established under Section 2203 of
Public Law 114–322, the Water
Infrastructure Improvements for the
Nation Act; 42 U.S.C. 300j–21, Registry
for Lead Exposure and Prevention
Advisory Committee.
Purpose: The LEPAC is charged with
providing advice and guidance to the
Secretary, Department of Health and
Human Services (HHS), and the
Director, CDC and Administrator,
ATSDR, on (1) reviewing Federal
programs and services available to
individual communities exposed to
lead; (2) reviewing current research on
lead exposure to identify additional
research needs; (3) reviewing and
identifying best practices, or the need
for best practices regarding lead
screening and the prevention of lead
poisoning; (4) identifying effective
services, including services relating to
healthcare, education, and nutrition for
individuals and communities affected
by lead exposure and lead poisoning,
including in consultation with, as
appropriate, the lead exposure registry
as established in Section 2203(b) of
Public Law 114–322; and (5)
undertaking any other review or
activities that the Secretary determines
to be appropriate.
Matters to be Considered: The agenda
will include presentations and
discussions on the following topics:
vote on the 2023 annual LEPAC report,
report from the Preventing Lead
Exposure in Adults workgroup, lead
PO 00000
Frm 00081
Fmt 4703
Sfmt 9990
related updates from the LEPAC
members, local perspective on
improving blood lead testing, blood lead
testing strategies. Agenda items are
subject to change as priorities dictate.
Public Participation
Oral Public Comment: The public
comment period is scheduled on
December 11, 2024, from 12:30 p.m.
until 12:50 p.m., EST. Individuals
wishing to make a comment during the
public comment period, please email
your name, organization, and phone
number by November 25, 2024, to
LEPAC@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–24925 Filed 10–24–24; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 89, Number 207 (Friday, October 25, 2024)]
[Notices]
[Pages 85215-85216]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24922]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-25-1385; Docket No. CDC-2024-0084]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a continuing information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled Characteristics of Cases of Priority Fungal Diseases. These case
report forms (CRF) collect information on patient demographics,
underlying conditions, diagnosis, treatments, healthcare utilization,
and outcomes of patients with coccidioidomycosis, histoplasmosis,
blastomycosis, Candida auris, triazole-resistant Aspergillus fumigatus
infection or colonization, or antifungal-resistant dermatophytosis,
chromoblastomycosis, mycetoma, and sporotrichosis.
DATES: CDC must receive written comments on or before December 24,
2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0084 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Cases of Priority Fungal Diseases (OMB Control
No. 0920-1385, Exp. 4/30/2027)--Revision--National Center for Emerging
and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Fungal diseases cause substantial illness, ranging from mild
infection to severe or life-threatening invasive disease. They also
constitute a considerable financial burden on patients and healthcare
systems. Awareness of fungal diseases is low, and data collection has
historically been limited in size, scope, and coordination, which has
hindered our understanding of these diseases. Detailed epidemiologic
and clinical data are critical to inform appropriate public health
responses.
CDC plans to enhance surveillance of high priority fungal diseases
across the United States to better characterize factors such as disease
burden, geographic scope, patient risk factors, health disparities,
healthcare utilization, outcomes, and emerging trends. This project
will serve as a Revision to the information collection project
Characteristics of Cases of Priority Fungal Diseases (OMB Control No.
0920-1385). The Revision will expand the number of fungal diseases for
which data may be collected. In addition to triazole-resistant A.
fumigatus infections, coccidioidomycosis, histoplasmosis,
blastomycosis, C. auris, and antifungal-resistant dermatophytosis, Case
Report Forms (CRF) have also been developed for chromoblastomycosis,
mycetoma, and sporotrichosis.
CDC plans to use standardized CRFs to collect public health
surveillance data for cases of these diseases regarding demographics
(e.g., age, sex, race/ethnicity, location of residence), underlying
medical conditions, diagnosis (e.g., clinical presentation, laboratory
testing), treatments, and outcomes (e.g., hospitalization, vital
status). The corresponding CRF would be filled out voluntarily by
state, local or tribal health departments, federal agencies, and
members of the private sector (e.g., academic institutions), and
contains a section for medical chart review and an optional
supplemental interview (including data on potential occupational or
environmental exposures) of the patient or their representative.
Findings can help identify populations at higher risk of these
diseases, detect emerging epidemiologic trends, and guide prevention
and response efforts. They can also help better focus public and
healthcare provider outreach, inform efforts to contain or mitigate
spread, and influence health policy and research on prevention and
treatment.
[[Page 85216]]
CDC requests OMB approval for an estimated 1,564 annual burden
hours. There is no cost to respondents other than their time to
participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Avg. burden
Number of Number per Total
Form name Type of respondent respondents responses per response burden (in
respondent (in hrs.) hrs.)
----------------------------------------------------------------------------------------------------------------
Triazole-resistant Aspergillus State and Local 15 15 0.5 113
fumigatus Case Report Form. Health Departments.
Coccidioidomycosis Case Report State and Local 10 25 1.0 250
Form. Health Departments.
Private Sectors..... 3 10 1.0 30
Histoplasmosis Case Report Form.. State and Local 10 25 1.0 250
Health Departments.
Private Sectors..... 3 10 1.0 30
Blastomycosis Case Report Form... State and Local 10 25 1.0 250
Health Departments.
Private Sectors..... 3 10 1.0 30
Candida auris Case Report Form... State and Local 15 20 0.75 225
Health Departments.
Private Sectors..... 3 10 0.75 23
Antifungal-resistant State and Local 10 10 0.5 50
dermatophytosis case report form. Health Departments.
Chromoblastomycosis case report Private Sectors..... 25 10 0.5 125
form.
Mycetoma case report form........ Private Sectors..... 25 5 0.5 63
Sporotrichosis case report form.. Private Sectors..... 25 10 0.5 125
--------------------------------------------------------
Total........................ .................... ............ ............... ........... 1,564
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-24922 Filed 10-24-24; 8:45 am]
BILLING CODE 4163-18-P
